Video Library
Contraindications of NSAIDs
Contraindications of NSAIDs ( 5 Questions)
A nurse is teaching a client who has osteoarthritis and is prescribed celecoxib (Celebrex), a selective COX-2 inhibitor. What should the nurse include in the teaching?
This is because celecoxib (Celebrex), a selective COX-2 inhibitor, selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which is responsible for prostaglandin synthesis in inflammation, pain, and fever¹. Prostaglandins produced by the cyclooxygenase-1 (COX-1) enzyme, which is not affected by celecoxib, have protective effects on the gastrointestinal mucosa and platelet function¹. Therefore, celecoxib has less risk of causing gastrointestinal ulceration and bleeding than nonselective COX inhibitors, which block both COX-1 and COX-2 enzymes²³.
Celecoxib does not block both COX-1 and COX-2 enzymes, but only COX-2 enzyme. Therefore, it does not have more anti-inflammatory and analgesic effects than nonselective COX inhibitors, but similar effects .
Celecoxib does not inhibit vasodilatory and antiplatelet prostaglandins produced by COX-2 in the endothelium, but rather it inhibits the production of these prostaglandins by COX-2 in the inflammatory sites. Therefore, it does not have less cardiovascular risk than nonselective COX inhibitors, but more risk .
Celecoxib does not block the production of prostaglandins involved in fever and platelet aggregation, but rather it spares the production of these prostaglandins by COX-1. Therefore, it does not have more antipyretic and antiplatelet effects than nonselective COX inhibitors, but none or minimal effects .
A. The drug has less gastrointestinal toxicity than nonselective COX inhibitors because it does not interfere with gastric mucosal protection by prostaglandins.
This is because celecoxib (Celebrex), a selective COX-2 inhibitor, selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which is responsible for prostaglandin synthesis in inflammation, pain, and fever¹. Prostaglandins produced by the cyclooxygenase-1 (COX-1) enzyme, which is not affected by celecoxib, have protective effects on the gastrointestinal mucosa and platelet function¹. Therefore, celecoxib has less risk of causing gastrointestinal ulceration and bleeding than nonselective COX inhibitors, which block both COX-1 and COX-2 enzymes²³.
The other options are wrong because they are either false or contradictory to the facts about celecoxib (Celebrex), a selective COX-2 inhibitor.
- Option B is wrong because celecoxib does not block both COX-1 and COX-2 enzymes, but only COX-2 enzyme. Therefore, it does not have more anti-inflammatory and analgesic effects than nonselective COX inhibitors, but similar effects .
- Option C is wrong because celecoxib does not inhibit vasodilatory and antiplatelet prostaglandins produced by COX-2 in the endothelium, but rather it inhibits the production of these prostaglandins by COX-2 in the inflammatory sites. Therefore, it does not have less cardiovascular risk than nonselective COX inhibitors, but more risk .
- Option D is wrong because celecoxib does not block the production of prostaglandins involved in fever and platelet aggregation, but rather it spares the production of these prostaglandins by COX-1. Therefore, it does not have more antipyretic and antiplatelet effects than nonselective COX inhibitors, but none or minimal effects .
